KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Payables (2016 - 2025)

Quest Diagnostics' Payables history spans 17 years, with the latest figure at $1.6 billion for Q4 2025.

  • For Q4 2025, Payables rose 14.78% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $1.6 billion, up 14.78%, while the annual FY2025 figure was $1.6 billion, 14.78% up from the prior year.
  • Payables for Q4 2025 was $1.6 billion at Quest Diagnostics, up from $1.5 billion in the prior quarter.
  • Across five years, Payables topped out at $1.6 billion in Q3 2021 and bottomed at $1.2 billion in Q3 2023.
  • The 5-year median for Payables is $1.4 billion (2022), against an average of $1.4 billion.
  • The largest annual shift saw Payables surged 58.92% in 2021 before it dropped 22.41% in 2023.
  • A 5-year view of Payables shows it stood at $1.6 billion in 2021, then fell by 12.75% to $1.4 billion in 2022, then decreased by 2.65% to $1.4 billion in 2023, then rose by 2.58% to $1.4 billion in 2024, then grew by 14.78% to $1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for DGX's Payables are $1.6 billion (Q4 2025), $1.5 billion (Q3 2025), and $1.3 billion (Q2 2025).